# Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS

> **NCT00142987** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 664 (—)

## Conditions studied

- IBS-C and IBS With Mixed Bowel Habits

## Interventions

- **DRUG:** Tegaserod

## Key facts

- **NCT ID:** NCT00142987
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 664 (—)
- **Last updated:** 2008-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142987, "Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00142987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*